[go: up one dir, main page]

DK2070914T3 - Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse - Google Patents

Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Info

Publication number
DK2070914T3
DK2070914T3 DK09003174.1T DK09003174T DK2070914T3 DK 2070914 T3 DK2070914 T3 DK 2070914T3 DK 09003174 T DK09003174 T DK 09003174T DK 2070914 T3 DK2070914 T3 DK 2070914T3
Authority
DK
Denmark
Prior art keywords
medicines
preparation
new
methods
pharmaceutical compositions
Prior art date
Application number
DK09003174.1T
Other languages
English (en)
Inventor
Jean-Michel Lefrancois
Jean-Marie Ruxer
Bertrand Heckmann
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Application granted granted Critical
Publication of DK2070914T3 publication Critical patent/DK2070914T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09003174.1T 2002-11-19 2003-11-12 Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse DK2070914T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
EP03799611A EP1565467B1 (fr) 2002-11-19 2003-11-12 Nouveaux derives antagonistes du recepteur de la vitronectine leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
DK2070914T3 true DK2070914T3 (da) 2011-11-21

Family

ID=32187700

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09003174.1T DK2070914T3 (da) 2002-11-19 2003-11-12 Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse
DK03799611T DK1565467T3 (da) 2002-11-19 2003-11-12 Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03799611T DK1565467T3 (da) 2002-11-19 2003-11-12 Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Country Status (28)

Country Link
US (2) US7582640B2 (da)
EP (2) EP1565467B1 (da)
JP (1) JP4567459B2 (da)
KR (1) KR101140752B1 (da)
CN (2) CN101928287A (da)
AR (2) AR042068A1 (da)
AT (2) ATE518842T1 (da)
AU (2) AU2003299330B2 (da)
BR (1) BR0316307A (da)
CA (1) CA2506310C (da)
CO (1) CO5700761A2 (da)
CY (1) CY1112218T1 (da)
DE (1) DE60327712D1 (da)
DK (2) DK2070914T3 (da)
ES (2) ES2369561T3 (da)
FR (1) FR2847254B1 (da)
HK (2) HK1076277A1 (da)
IL (2) IL168136A (da)
MA (1) MA27492A1 (da)
MX (1) MXPA05005340A (da)
NO (1) NO20052491D0 (da)
PL (1) PL376866A1 (da)
PT (2) PT1565467E (da)
RU (1) RU2412185C2 (da)
SI (2) SI2070914T1 (da)
TW (1) TW200412969A (da)
WO (1) WO2004048375A1 (da)
ZA (1) ZA200502850B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
AU2019326932A1 (en) 2018-08-17 2021-03-18 Oxurion NV Integrin antagonists
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A4 (en) 2020-06-29 2024-07-24 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
AU675689B2 (en) 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
MX9700041A (es) 1994-06-29 1997-04-30 Smithkline Beecham Corp Antagonistas de receptor de vitronectina.
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
EP0907637A1 (de) 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
EP1049677A1 (en) 1998-01-23 2000-11-08 Aventis Pharma Deutschland GmbH Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
AU3213799A (en) * 1998-04-01 1999-10-18 Du Pont Pharmaceuticals Company Integrin antagonists
CN1322133A (zh) * 1998-08-07 2001-11-14 史密丝克莱恩比彻姆公司 玻璃体结合蛋白受体拮抗剂
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
JP4216499B2 (ja) * 1999-10-05 2009-01-28 デ ビアス インダストリアル ダイアモンズ （プロプライエタリイ）リミテッド ダイヤモンドクラスターの成長
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
CO5700761A2 (es) 2006-11-30
EP1565467A1 (fr) 2005-08-24
KR20050083926A (ko) 2005-08-26
ATE518842T1 (de) 2011-08-15
HK1076277A1 (en) 2006-01-13
MXPA05005340A (es) 2005-11-17
NO20052491L (no) 2005-05-23
US7582640B2 (en) 2009-09-01
JP2006508999A (ja) 2006-03-16
AU2009212779B2 (en) 2011-09-01
CN101928287A (zh) 2010-12-29
PL376866A1 (pl) 2006-01-09
PT2070914E (pt) 2011-10-12
AU2003299330B2 (en) 2009-09-17
AU2003299330A1 (en) 2004-06-18
AR077476A2 (es) 2011-08-31
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
ZA200502850B (en) 2005-10-25
CN1738817A (zh) 2006-02-22
BR0316307A (pt) 2005-09-27
SI2070914T1 (sl) 2012-02-29
EP1565467B1 (fr) 2009-05-20
US20090149476A1 (en) 2009-06-11
DE60327712D1 (de) 2009-07-02
IL205693A (en) 2011-06-30
CA2506310A1 (fr) 2004-06-10
WO2004048375A1 (fr) 2004-06-10
AU2009212779A1 (en) 2009-09-17
RU2005119163A (ru) 2006-02-27
ES2369561T3 (es) 2011-12-01
HK1129372A1 (en) 2009-11-27
AR042068A1 (es) 2005-06-08
FR2847254B1 (fr) 2005-01-28
CN1738817B (zh) 2011-12-21
TW200412969A (en) 2004-08-01
ES2325616T3 (es) 2009-09-10
EP2070914A1 (fr) 2009-06-17
IL168136A (en) 2012-06-28
JP4567459B2 (ja) 2010-10-20
PT1565467E (pt) 2009-07-15
RU2412185C2 (ru) 2011-02-20
NO20052491D0 (no) 2005-05-23
DK1565467T3 (da) 2009-09-14
US20060052398A1 (en) 2006-03-09
CY1112218T1 (el) 2015-12-09
FR2847254A1 (fr) 2004-05-21
ATE431825T1 (de) 2009-06-15
CA2506310C (fr) 2014-04-08
SI1565467T1 (sl) 2009-10-31
EP2070914B1 (fr) 2011-08-03
KR101140752B1 (ko) 2012-05-03

Similar Documents

Publication Publication Date Title
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
DK1601363T3 (da) Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
NO20051645L (no) Nye aminoindozolderivater som medisin og farmakologiske preparater inneholdende disse
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DK1720544T3 (da) Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
IS2991B (is) Lyfjafræðileg nanóagna samsetning takykínín viðtakamótlyfs
IL180488A0 (en) Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof of kinase inhibitors
NO20080484L (no) Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
HK1129372A1 (en) New antagonist derivatives of the vitronectin receptor, method for their preparation, their application as medicine and pharmaceutical compositions containing them
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
DK1696913T3 (da) Vinfluninholdigt farmaceutisk præparat til parenteral administration, fremgangsmåde til fremstilling deraf og dets anvendelse
NO331227B1 (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer
DK1655030T3 (da) Benzothiadiazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
DK1277746T3 (da) Nye N-benzylpiperazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
DK1757586T3 (da) Nye polysubstituerede 1,1-pyridinylaminocyclopropanaforbindelser, fremgangsmåder til fremstilling heraf og farmaceutisk sammensætning, som indeholder disse